BioAge Labs is a clinical-stage biopharmaceutical company dedicated to developing therapies that target the biology of human aging to treat metabolic diseases. Their lead program, azelaprag, is an oral weight loss therapy designed to be co-administered with incretin drugs, aiming to achieve significant weight loss and improved body composition. Utilizing a human-first discovery platform, BioAge analyzes proprietary multi-omics data to identify molecular mediators of aging and disease, enabling the development of a diverse pipeline addressing key pathways in metabolic aging.